Ravulizumab for the treatment of myasthenia gravis.
Expert opinion on biological therapy（2023）
摘要
Data of the CHAMPION MG trial demonstrate that ravulizumab is effective and safe in the treatment of generalized MG. Having a rapid clinical effect, with long-term clinical response, ravulizumab could represent a selective immunosuppressive drug of choice in the future therapeutic algorithm of MG, where conventional immunosuppressants slowly leave room for newer drugs with a more targeted mechanism of action.
更多查看译文
关键词
C5 inhibition,Myasthenia gravis,biological drugs,complement cascade,eculizumab,immunosuppression,monoclonal antibody,ravulizumab
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要